Xizang Haisco Pharmaceutical Group Co Ltd

Here is the public summary page for Xizang Haisco Pharmaceutical Group Co Ltd. Please login to see the complete information for Xizang Haisco Pharmaceutical Group Co Ltd including detailed analysis of price, sentiment, fundamentals, flow, forecast models, alerts and much more. Also you can see how Xizang Haisco Pharmaceutical Group Co Ltd stacks up relative to its peers.


Darwin Score+32
Ticker002653
Latest Price60.30 CNY as of close on 15-Aug-2025
3 Month price range40.99 to 60.30 CNY
Market Capitalisation67.53Bn CNY
CountryChina
RegionEurope
Economic SectorHealth Care
Business SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryPharmaceuticals
Sub-IndustryPharmaceuticals
Description
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products in China. The company offers anesthetic analgesic, neuropsychiatric system, and digestive liver and parenteral nutrition medications; drugs for the endocrine and cardiovascular system; oncology-related drugs; andrology drugs; desonide and liprocaine cream; propofol medium/long chain fat emulsion and hydroxyethyl starch sodium chloride injection; sodium fusidicate ointment; lupatadine fumarate tablets; and caspofungin acetate and methylprednisolone sodium succinate for injection. It also develops Sisuning for sedation and anesthesia during surgery/procedure for non-endotracheal intubation, general anesthesia induction and maintenance, sedation in mechanical ventilation during intensive care, pediatric indications, and general anesthesia induction; Simenine for diabetic peripheral neuralgia, postherpetic neuralgia, and central nervous system analgesia; Beichangping for type 2 diabetes; Sysojing for postoperative analgesia of abdominal surgery, chronic kidney disease itching, orthopedic analgesia, and postoperative nausea and vomiting; HSK31858 for non-cystic fibrosis bronchiectasis, bronchial asthma, chronic obstructive pulmonary disease, and expectorant; HSK31679 for nonalcoholic steatohepatitis; HSK39297 for PHN of hemolytic disease and primary or secondary glomerular disease; HSK39775 and HSK42360 for advanced solid tumors; HSK39004 and HL231 for chronic obstructive pulmonary disease; HSK44459 for interstitial lung disease; HSK46575 for prostate cancer; and HSK41959 for advanced solid tumors. It offers its products for anesthesia, analgesia, chronic metabolic, respiratory, autoimmune diseases, etc. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2005 and is based in Shannan, China.
See More ...
Company URLhttps://www.haisco.com
See Darwins Full Analysis for Xizang Haisco Pharmaceutical Group Co Ltd

Tell Me About

Tell Me About (TMA) is Darwins structured scoring system for assets. Here are the scores from the key TMA sections for Xizang Haisco Pharmaceutical Group Co Ltd. Further information and full detail is available when you login.

TMA PartFocus of AnalysisTMA Score
PriceAnalysis of performance, trend, RSI, OBV and moving averages+30
SentimentNews and Candle Patterns. -1
FundamentalsAnalyst Ratings, Valuation and Dividend analysis.-11
FlowInstitutional, Fund and Insider buying and selling.0
ModelsForecast models.+14

Alerts

There are 10 live alerts for Xizang Haisco Pharmaceutical Group Co Ltd.


Peer Comparison

There are 7 peers of Xizang Haisco Pharmaceutical Group Co Ltd.
Asset NameIndustry GroupPerf(20d)%Asset Score
Changchun High & New Technology Industries Group Inc (000661)Pharmaceuticals+0.3+9
China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999)Pharmaceuticals-0.9-5
Shan Dong Dong-E E-Jiao Co Ltd (000423)Pharmaceuticals+1.00
Shenzhen Salubris Pharmaceuticals Co Ltd (002294)Pharmaceuticals-7.6+19
Sichuan Kelun Pharmaceutical Co Ltd (002422)Pharmaceuticals+2.6+28
Yunnan Baiyao Group Co Ltd (000538)Pharmaceuticals-0.5-7
Zhejiang Nhu Co Ltd (002001)Pharmaceuticals+4.7+34

Share Share on Facebook Share on Twitter Share on Threads Share on LinkedIn